Showing 2,741 - 2,760 results of 20,793 for search '"therapy"', query time: 0.10s Refine Results
  1. 2741
  2. 2742
  3. 2743
  4. 2744

    In vitro effect of hCG on cryptorchid patients’ gubernacular cells: a predictive model for adjuvant personalized therapy by Andrea Errico, Giulia Ambrosini, Sara Vinco, Emanuela Bottani, Elisa Dalla Pozza, Nunzio Marroncelli, Jessica Brandi, Daniela Cecconi, Ilaria Decimo, Filippo Migliorini, Nicola Zampieri, Ilaria Dando

    Published 2025-01-01
    “…The most effective method to treat cryptorchidism is orchiopexy, followed by human chorionic gonadotropin (hCG) therapy; however, a portion of treated patients do not show a significant improvement in testis volume and vascularization after adjuvant therapy. …”
    Get full text
    Article
  5. 2745

    A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy by Emi Hata, Masatoshi Miyauchi, Nobuhiko Noguchi, Takeshi Asami

    Published 2025-01-01
    “…Clinicians should be aware of the potential interactions and closely monitor for signs of EPS during such therapy adjustments.…”
    Get full text
    Article
  6. 2746

    Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy by Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani, Hanna Sanoff, Reza Hadi, Esmat Samiei, Alan P. Venook, Mark J. Ratain, Naim Rashid, Benjamin G. Vincent, Xueping Qu, Yujia Wen, Michael Kosorok, William F. Symmans, John Paul Y. C. Shen, Michael S. Lee, Scott Kopetz, Andrew B. Nixon, Monica M. Bertagnolli, Charles M. Perou, Federico Innocenti

    Published 2025-01-01
    “…Our study discerns sets of genes, each forming a signature that collectively contribute to define patient subgroups with different prognosis and response to the therapies. Using an external cohort, we show that the genes influencing OS within the signatures, such as FANCI and PRC1, are upregulated in CRC tumor vs. normal tissue. …”
    Get full text
    Article
  7. 2747
  8. 2748
  9. 2749

    Management of the Pregnant Inflammatory Bowel Disease Patient on Antitumour Necrosis Factor Therapy: State of the Art and Future Directions by Yvette PY Leung, Remo Panaccione, Subrata Ghosh, Cynthia H Seow

    Published 2014-01-01
    “…When educated about the safety of anti-TNF therapy during pregnancy, patients often choose to continue on therapy during the third trimester.…”
    Get full text
    Article
  10. 2750
  11. 2751
  12. 2752

    Technical Feasibility of Acoustic Coordinated Reset Therapy for Tinnitus Delivered via Hearing Aids: A Case Study by Christian Hauptmann, Mark Williams, Federica Vinciati, Markus Haller

    Published 2017-01-01
    “…He was subsequently treated with the therapy being deployed through a set of contemporary hearing aids. …”
    Get full text
    Article
  13. 2753
  14. 2754

    Investigating Non-steroidal Anti-Inflammatory Drugs as Potential Cancer Adjuncts: A Novel Approach to Cancer Therapy by Sadaf Alam, Leena Anjum, Muhammad Haneef

    Published 2025-02-01
    “…These drugs reduce inflammation and regulate key biological pathways involved in cancer progression, offering new avenues for prevention and therapy. Methodology: A comprehensive review of clinical, epidemiological, and experimental studies was conducted to assess the roles of NSAIDs including aspirin, meloxicam, celecoxib, sulindac, naproxen, indomethacin, and piroxicam, in cancer treatment. …”
    Get full text
    Article
  15. 2755
  16. 2756

    Online cognitive–behavioural therapy for traumatically bereaved people: study protocol for a randomised waitlist-controlled trial by Jos de Keijser, Lonneke Lenferink, Maarten Eisma, Geert Smid, Paul Boelen

    Published 2020-09-01
    “…Waitlist-controlled trials have shown that grief-specific cognitive–behavioural therapy (CBT) is an effective treatment for such mental health problems. …”
    Get full text
    Article
  17. 2757
  18. 2758
  19. 2759

    Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study by Øystein Kalsnes Jørstad, Morten Carstens Moe, Morten Wang Fagerland, Yngvil Solheim Husum, Erik Fink Eriksen

    Published 2024-12-01
    “…Aims To assess the feasibility of a study protocol for a randomised controlled trial of zoledronic acid (ZA) as adjuvant therapy for neovascular age-related macular degeneration (nAMD).Methods In this 1-year, randomised, double-blinded, placebo-controlled pilot study, nAMD patients were allocated 1:1 to receive intravenous ZA 5 mg or placebo at baseline and after 6 months in addition to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy following a treat-and-extend regimen. …”
    Get full text
    Article
  20. 2760